Imagine a future where medical advances can cure deadly diseases such as lung cancer, offering a chance at a second life. This is the vision of Berlin-based startup Tomorrow.Bio, Europe’s first cryonics lab, who just raised a €5 million Seed funding round.
The investment round was co-led by early-stage VC firm Blast.Club and Truventuro, the Family Office of Nils Regge.
“We’re extremely happy to have found visionary investors to continue our long-term mission. Not only by expanding our coverage to the US but also by doubling down on R&D to further improve preservation quality and stay far ahead of all competition,” said Dr Emil Kendziorra, Founder and CEO of Tomorrow.Bio.
Tomorrow.Bio was founded by Dr Emil Kendziorra and Fernando Azevedo Pinheiro in 2020. Kendziorra is a doctor and former cancer researcher who switched careers after finding “progress in curing the disease way too slow“. Prior to Tomorrow.Bio, Kendziorra and Pinheiro each founded and exited tech companies.
The company offers long-term cryopreservation services for individuals who choose to be stored at ultra-low temperatures after legal death, with the goal of potentially being revived in the future when medical technologies have advanced.
Tomorrow.Bio operates in close collaboration with the European Biostasis Foundation (EBF) in Switzerland, where patients are preserved in high-tech facilities using vacuum-insulated dewars filled with liquid nitrogen.
As of today, the company has cryopreserved 20 people and 10 pets, with more than 800 more signed up. Total contract value has just surpassed €160 million.
Cryopreservation involves exposing the body to extremely low temperatures – minus 196°C- to halt all biological processes. Tomorrow.Bio operates a fleet of specially equipped cryo-ambulances that retrieve the deceased and initiate the cooling process while en route to the storage facility in Switzerland.
These ‘standby teams,’ currently based in Berlin and Zurich, with additional units being established at multiple locations in Europe and the US, perform chest compressions, supply oxygen and start a specialised cooling process to slow decomposition after legal pronouncement.
They also replace all body fluids with a cryoprotectant solution—an antifreeze-like substance that prevents harmful ice crystal formation as the temperature drops. With its expansion into the U.S. and plans to establish partner medical teams in at least three additional locations, Tomorrow.Bio is poised looks to become the first company globally to offer local teams that begin the process immediately.
“Companies like Tomorrow Bio are on the absolute forefront of visionary longevity approaches. We’re very happy to support these types of moonshots, that might not just have a big impact on the extension of life span but are also huge business opportunities,” said Nils Regge, Founder of Truventuro and investor in longevity.
The company collaborates with its sister organisation, the European Biostasis Foundation, located in the Swiss village of Rafz, where cryopreserved patients are ultimately housed. In a state-of-the-art facility within an industrial park, patients are preserved in vacuum insulated steel containers, known as dewars, which stand 3.2 meters tall. These dewars are filled with liquid nitrogen and require no electricity to maintain freezing conditions.
“Tomorrow Bio’s cutting-edge technology is revolutionising the way we view life and death. The company has the necessary assets to overcome technological challenges and ensure sustainable growth. The ambitious yet realistic vision of the founders Emil and Fernando positions Tomorrow Bio as what could be the future of medicine,” said Anthony Bourbon, Founder and CEO of Blast.Club .
Tomorrow.Bio will use the funds to expand into the United States, with initial locations in the States of New York, California and Florida. Furthermore, the company will double down on R&D to further improve preservation quality.
Read the orginal article: https://www.eu-startups.com/2025/05/cryo-now-heal-later-europes-first-cryonics-lab-tomorrow-bio-eyes-u-s-expansion-with-e5-million-in-fresh-funding/
